Skip to main content

Herceptin Hylecta

NDC 50242-077 · Genentech, Inc.

Generic nameTrastuzumab and hyaluronidase-oysk
Dosage formINJECTION, SOLUTION
RouteSUBCUTANEOUS
Active ingredient(s)TRASTUZUMAB, HYALURONIDASE (HUMAN RECOMBINANT)
Strength10000; 600 U/5mL; mg/5mL
Pharmacologic classEndoglycosidase [EPC], Glycoside Hydrolases [CS], HER2/Neu/cerbB2 Antagonists [MoA], HER2/neu Receptor Antagonist [EPC]
Marketing categoryBLA

Packages

50242-077-01 — 1 VIAL, SINGLE-DOSE in 1 CARTON (50242-077-01) / 5 mL in 1 VIAL, SINGLE-DOSE

Billed under HCPCS

J9356 — Injection, trastuzumab, 10 mg and hyaluronidase-oysk Medicare Part B payment limit (ASP + 6%): $58.34

Related Codes

Same active ingredient

FDA lists these products with the same active ingredient.

0003-3120 — nivolumab and hyaluronidase-nvhy, 0003-6120 — nivolumab and hyaluronidase-nvhy, 0069-0308 — trastuzumab-qyyp, 18657-117 — Hyaluronidase, 50242-108 — rituximab and hyaluronidase, 50242-109 — rituximab and hyaluronidase, 50242-132 — Trastuzumab, 50242-245 — pertuzumab, trastuzumab, and hyaluronidase-zzxf, 50242-260 — pertuzumab, trastuzumab, and hyaluronidase-zzxf, 50242-554 — ocrelizumab and hyaluronidase, 50242-933 — atezolizumab and hyaluronidase-tqjs, 51662-1555 — HYALURONIDASE, 55513-132 — trastuzumab-anns, 55513-141 — trastuzumab-anns, 57894-503 — daratumumab and hyaluronidase-fihj (human recombinant), 57894-510 — AMIVANTAMAB and HYALURONIDASE-lpuj (HUMAN RECOMBINANT), 57894-514 — AMIVANTAMAB and HYALURONIDASE-lpuj (HUMAN RECOMBINANT), 57894-515 — AMIVANTAMAB and HYALURONIDASE-lpuj (HUMAN RECOMBINANT), 57894-522 — AMIVANTAMAB and HYALURONIDASE-lpuj (HUMAN RECOMBINANT), 63459-303 — TRASTUZUMAB, +6 more

From the FDA National Drug Code Directory, retrieved 2026-08-24. Product listings are submitted by labelers; FDA does not verify them.